Ingress Health – a Cytel Company
  • Home
  • Why Ingress
    • Our vision & values
    • White papers
    • Careers
    • Testimonials
    • Partners
    • Ingress Helps
    • Ingress University
  • Team
  • Services
      • Real-World Evidence
        • Prospective observational studies
        • Pragmatic randomized trials
        • Chart reviews
        • Patient reported outcomes
        • Preference Studies
        • RWE Databases
      • Health economics
        • Cost-effectiveness modelling
        • Country adaptations
        • Early cost-effectiveness modelling
        • Budget impact modelling
      • Evidence synthesis
        • Systematic literature reviews
        • Network meta-analyses
        • End-point validation studies
      • Strategic market access
        • HEOR and pricing strategies
        • Global Value dossier
        • Reimbursement dossiers
        • Dashoards
      • Education
  • Track record
      • Services
        • For our publications on the different services
      • Diseases
        • For our disease specific publications
      • EU Health Authorities
        • For an overview of the health authorities that evaluated our research for reimbursement purposes
  • All news
  • Contact

Incidence and prevalence of epilepsy in Germany

Home / All news / Incidence and prevalence of epilepsy in Germany

Classification of COPD severity according to GOLD
Patient preferences on treatment of rrMultiple Myeloma
  • 1 november 2017

You can download the poster from here.

Recent posts

  • Questionnaire for the identification of non-adherence barriers in patients receiving intravitreal injection
  • We have set a high standard
  • New Publication!
  • Building Muscles for Those Who Can’t!
  • HEOR & RWE Solution Center

Quick links

  • Home
  • Team
  • Services
    • Real-World Evidence
  • Why Ingress
  • Track record
  • Contact
  • Data Privacy Policy

Link up

Ingress health – NL

Weena 316-318
3012 NJ Rotterdam
Netherlands

Ingress health – DE

Alter Holzhafen 19 Potsdamer Str. 58
23966 Wismar 10785 Berlin
Germany Germany
© 2022 Ingress Health - a Cytel Company
  • Home
  • Disclaimer
  • Data Privacy Policy
Ingress Health
  • Home
  • Why Ingress
    • Our vision & values
    • White papers
    • Careers
    • Testimonials
    • Partners
    • Ingress Helps
    • Ingress University
    • Back
  • Team
  • Services
    • Real-World Evidence
      • Prospective observational studies
      • Pragmatic randomized trials
      • Chart reviews
      • Patient reported outcomes
      • Preference Studies
      • RWE Databases
      • Back
    • Health economics
      • Cost-effectiveness modelling
      • Country adaptations
      • Early cost-effectiveness modelling
      • Budget impact modelling
      • Back
    • Evidence synthesis
      • Systematic literature reviews
      • Network meta-analyses
      • End-point validation studies
      • Back
    • Strategic market access
      • HEOR and pricing strategies
      • Global Value dossier
      • Reimbursement dossiers
      • Dashoards
      • Back
    • Education
    • Back
  • Track record
    • Services
      • For our publications on the different services
      • Back
    • Diseases
      • For our disease specific publications
      • Back
    • EU Health Authorities
      • For an overview of the health authorities that evaluated our research for reimbursement purposes
      • Back
    • Back
  • All news
  • Contact